News
AAPG
25.69
+0.94%
0.24
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (HIMS), Zimmer Biomet Holdings (ZBH) and Ascentage Pharma Group International Unsponsored ADR (AAPG)
TipRanks · 1d ago
BTIG Reiterates Buy on Ascentage Pharma Group, Maintains $48 Price Target
Benzinga · 1d ago
Weekly Report: what happened at AAPG last week (0406-0410)?
Weekly Report · 1d ago
Ascentage Pharma files Form 3 for Chief Accounting Officer Cao Jin
Reuters · 4d ago
Piper Sandler Remains a Buy on Ascentage Pharma Group International Unsponsored ADR (AAPG)
TipRanks · 4d ago
Applied Digital, Simply Good Foods And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Benzinga · 5d ago
Ascentage Pharma management to meet with Piper Sandler
TipRanks · 6d ago
Weekly Report: what happened at AAPG last week (0330-0403)?
Weekly Report · 04/06 09:14
CICC Sticks to Their Buy Rating for Ascentage Pharma Group International (6855)
TipRanks · 04/05 05:45
Ascentage Pharma management to meet with BTIG
TipRanks · 04/02 15:00
Ascentage Pharma relocates Hong Kong principal office to Central district
Reuters · 04/01 14:16
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 04/01 12:05
Why nCino Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
Benzinga · 04/01 09:27
Weekly Report: what happened at AAPG last week (0323-0327)?
Weekly Report · 03/30 09:14
Analysts Conflicted on These Healthcare Names: Ascentage Pharma Group International Unsponsored ADR (AAPG), Rocket Pharmaceuticals (RCKT) and Rhythm Pharmaceuticals (RYTM)
TipRanks · 03/27 11:50
Truist Financial Remains a Buy on Ascentage Pharma Group International Unsponsored ADR (AAPG)
TipRanks · 03/27 11:39
BTIG Remains a Buy on Ascentage Pharma Group International Unsponsored ADR (AAPG)
TipRanks · 03/27 10:57
Ascentage Pharma Group International GAAP EPS of $0.50 beats by $1.66
Seeking Alpha · 03/26 11:07
Ascentage Pharma FY2025; Lisatoclax sales climb to CNY 71 million; loss widens to CNY 1,243 million
Reuters · 03/25 22:33
Ascentage Pharma FY2025 operating loss widens 206.4% to RMB1.2 billion; revenue drops to RMB574.1 million due to no intellectual property revenue
Reuters · 03/25 22:32
More
Webull provides a variety of real-time AAPG stock news. You can receive the latest news about Ascentage Pharma Group International through multiple platforms. This information may help you make smarter investment decisions.
About AAPG
Ascentage Pharma Group International is an investment holding company primarily engaged in the discovery, development, and commercialization of therapies for hematologic malignancies. The Company's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The Company's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and multiple myeloma (MM). The Company primarily conducts its businesses in domestic market.